As researchers scramble to develop compounds that will be even safer and more effective for weight loss than currently ...

Eli Lilly's experimental weight-loss pill showed superior blood sugar control in diabetic patients across two late-stage ...

Eli Lilly said on Wednesday its experimental pill, orforglipron, helped reduce blood sugar levels in two late-stage trials. The oral drug is designed to mimic the appetite-suppressing GLP-1 hormone ...

Lilly’s weight loss pill succeeds in late stage trial; Novo acquires a new drug; Pfizer on U.S.-China partnerships.

A Lilly experimental weight loss pill showed superior blood sugar control in diabetic patients across two late-stage clinical ...

Not only celebrities are increasingly turning to the so-called "weight loss injection" to shed pounds. Now, two studies ...

After beating Novo Nordisk’s semaglutide last month, Lilly’s much anticipated oral candidate orforglipron has taken down AstraZeneca’s Farxiga in a head-to-head trial.

People are trying mini doses of GLP-1 drugs to lose weight or maintain weight loss, but doctors urge caution, calling the ...

Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...